

**WEST**

Generate Collection

Print

L1: Entry 3 of 45

File: USPT

Aug 27, 2002

DOCUMENT-IDENTIFIER: US 6440736 B1

TITLE: Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules

## Detailed Description Text (89):

References 1. Laukkanen, M. L., Teeri, T. T. and Keinanen, K. (1993). Lipid-tagged antibodies: bacterial expression and characterization of a lipoprotein-single-chain antibody fusion protein. *Protein Eng.* 6:449-454. 2. Laukkanen, M. L., Alfthan, K. and Keinanen, K. (1994). Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. *Biochemistry.* 33:11664-11670. 3. de Kruif, J., Storm, G. van Bloois, L., and Logtenberg, T. (1996). Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immuroliposomes. *FEBS Lett.* 399:232-236. 4. de Kruif, J., Boel, E., and Logtenberg, T. (1995). Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. *J. Mol. Biol.* 248: 97-105. 5. de Kruif, J., Terstappen, L., Boel, E. and Logtenberg T. (1995). Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library. *Proc. Natl. Acad. Sci. USA.* 92:3938-3942. 6. Graziano, R. F. et al. (1995). Construction and characterization of a humanized anti-gamma-Ig receptor type I Fc.gamma.RI) monoclonal antibody. *J. Immunol.* 155:4996-5002. 7. Pack, P. et al. (1993). Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of *Escherichia coli*. *Bio/technology.* 11:1271-1277. 8. Grayeb, J. and Inouye, M. (1984). Nine amino acid residues at the NH2-terminal of lipoprotein are sufficient for its modification, processing and localization in the outer membrane of *Escherichia coli*. *J. Biol. Chem.* 259:463-467. 9. Grouard, G., de Bouteiller, O., Banchereau, J. and Liu, Y-J. (1995). Human follicular dendritic cells enhance cytokine-dependent growth and differentiation of CD40-activated B-cells. *J. Immunol.* 155:3345-3352. 10. Smiths, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. *Science.* 228:1315-1317. 11. Francisco, J. A., Earhart, C. F. and Georgiou, G. (1992). Transport and anchoring of beta-lactamase to the external surface of *Escherichia coli*. *Proc. Natl. Acad. Sci. USA.* 89:2713-2717. 12. Boder E. T. and Wittrup, K. D. (1997). Yeast surface display for screening combinatorial polypeptide libraries. *Nat. Biotechnol.* 15:553-557. 13. Eshhar, Z. (1997). Tumor-specific T-bodies: towards clinical application. *Cancer Immunol. Immunother.* 45:131-136. 14. Kwiatkowska, K. and Sobota, A. (1999). Signaling pathways in phagocytosis. *BioEssays.* 21:422-431. 15. Devitt, A. et al. (1998). Human CD14 mediates recognition and phagocytosis of apoptotic cells. *Nature* 392:505-509. 16. Sallusto, F. and Lanzavecchia, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. *J. Exp. Med.* 179: 1109-1114. 17. Gosselin, E. J., Wardwell, K., Gosselin, D. R., Alter, N. Fisher, J. L. and Guyre, P. M. (1992). Enhanced antigen presentation using human Fc.gamma. receptor (monocyte/macrophage)-specific immunogens. *J. Immunol.* 149:3477-3481. 18. Liu, C. et al. (1999). Fc.gamma.RI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and agonist cell epitopes. *J. Clin. Invest.* 98:2001-2007. 19. Ridge, J. P., Di Rosa, F., Matzinger P. (1998). A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. *Nature.* 393:474-478. 20. Nawrocki, S. and Mackiewicz, A. (1999). Genetically modified tumour vaccines-where we are today. *Cancer Treat. Rev.* 25:29-46. 21. Schirmacher, V., et al. (1999). Human tumor cell modification by virus infection. *Gene Ther.* 6:63-73. 22. Haas, C., Herold-Mende, C., Gerhards, R. and Schirmacher, V. (1999). An

effective strategy of human tumor vaccin modification by coupling bispecific costimulatory molecules. Cancer Gene Ther. 6:254-262. 23. Berd, D. et al. (1998). Autologous, hapten-modified vaccine as a treatment for human cancers. Semin. Oncol. 25: 646-653. 24. Gong, J., Chen, D., Kashiwaba, M. and Kufe, D. (1997). Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558-561. 25. Vermorken, J. B. et al. (1999). Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353:345-350.

\*\*\*

--U.S. Patents Fulltext (File 654) has been redesigned with new search and display features. See HELP NEWS 654 for information.

\*\*\*

--Connect Time joins DialUnits as pricing options on Dialog. See HELP CONNECT for information.

\*\*\*

--CLAIMS/US Patents (Files 340,341, 942) have been enhanced with both application and grant publication level in a single record. See HELP NEWS 340 for information.

\*\*\*

--SourceOne patents are now delivered to your email inbox as PDF replacing TIFF delivery. See HELP SOURCE1 for more information.

\*\*\*

--Important news for public and academic libraries. See HELP LIBRARY for more information.

\*\*\*

--Important Notice to Freelance Authors--  
See HELP FREELANCE for more information

\*\*\*

For information about the access to file 43 please see Help News43.

\*\*\*

#### NEW FILES RELEASED

\*\*\*Dialog NewsRoom - Current 3-4 months (File 990)

\*\*\*Dialog NewsRoom - 2002 Archive (File 993)

\*\*\*Dialog NewsRoom - 2001 Archive (File 994)

\*\*\*Dialog NewsRoom - 2000 Archive (File 995)

\*\*\*TRADEMARKSCAN-Finland (File 679)

\*\*\*TRADEMARKSCAN-Norway (File 678)

\*\*\*TRADEMARKSCAN-Sweden (File 675)

\*\*\*

#### UPDATING RESUMED

\*\*\*Delphes European Business (File 481)

\*\*\*

#### RELOADED

\*\*\*D&B Dun's Electronic Business Directory (File 515)

\*\*\*U.S. Patents Fulltext 1976-current (File 654)

\*\*\*Population Demographics (File 581)

\*\*\*Kompass Western Europe (File 590)

\*\*\*D&B - Dun's Market Identifiers (File 516)

#### REMOVED

\*\*\*Chicago Tribune (File 632)

\*\*\*Fort Lauderdale Sun Sentinel (File 497)

\*\*\*The Orlando Sentinel (File 705)

\*\*\*Newport News Daily Press (File 747)

\*\*\*U.S. Patents Fulltext 1980-1989 (File 653)

\*\*\*Washington Post (File 146)

\*\*\*Books in Print (File 470)

\*\*\*Court Filings (File 793)

\*\*\*Publishers, Distributors & Wholesalers of the U.S. (File 450)

\*\*\*State Tax Today (File 791)

\*\*\*Tax Notes Today (File 790)

\*\*\*Worldwide Tax Daily (File 792)

\*\*\*New document supplier\*\*\*

IMED has been changed to INFOTRIE (see HELP OINFOTRI)

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<

\*\*\*\*\*

\* \*\*

\*\*\*

File 1:ERIC 1966-2002/Oct 03  
(c) format only 2002 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

Cost is in DialUnits

? b 410

02nov02	10:52:35	User208760 Session D2198.1
\$0.33	0.095	DialUnits File1
\$0.33		Estimated cost File1
\$0.33		Estimated cost this search
\$0.33		Estimated total session cost 0.095 DialUnits

File 410:Chronolog(R) 1981-2002/Sep  
(c) 2002 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

? set hi ;set hi

HIGHLIGHT set on as ''

**HIGHLIGHT set on as ''**

? begin 5,73,155,399

02nov02	10:52:39	User208760 Session D2198.2
\$0.00	0.071	DialUnits File410
\$0.00		Estimated cost File410
\$0.01		TELNET
\$0.01		Estimated cost this search
\$0.34		Estimated total session cost 0.166 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2002/Oct W4  
(c) 2002 BIOSIS

\*File 5: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 73:EMBASE 1974-2002/Oct W4  
(c) 2002 Elsevier Science B.V.

\*File 73: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 155:MEDLINE(R) 1966-2002/Oct W4

\*File 155: Alert feature enhanced for multiple files, duplicates removal, customized scheduling. See HELP ALERT.

File 399:CA SEARCH(R) 1967-2002/UD=13718  
(c) 2002 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement. Alert feature enhanced for multiple files, etc. See HELP ALERT.

Set	Items	Description
-----	-------	-------------

? s (agonist?) (10n) (antibod?) (10n) (cd40) and (vaccin?)

403137	AGONIST?
1750059	ANTIBOD?
16031	CD40
131	AGONIST? (10N) ANTIBOD? (10N) CD40
362120	VACCIN?

S1 12 (AGONIST?) (10N) (ANTIBOD?) (10N) (CD40) AND (VACCIN?)

? rd s1

...completed examining records

S2 9 RD S1 (unique items)

? t s2/3/all

2/3/1 (Item 1 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)

(c) 2002 BIOSIS. All rts. reserv.

13267172 BIOSIS NO.: 200100474321  
CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the  
absence of tumor-antigen **vaccination**.  
AUTHOR: Kedl Ross M(a); Jordan Michael; Potter Terence; Kappler John;  
Marrack Philippa; Dow Steven  
AUTHOR ADDRESS: (a)3M Center, 3M Pharmaceuticals, Building 270-2S-06, St.  
Paul, MN, 55144-1000: rmkedl@mmm.com\*\*USA  
JOURNAL: Proceedings of the National Academy of Sciences of the United  
States of America 98 (19):p10811-10816 September 11, 2001  
MEDIUM: print  
ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

2/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13004788 BIOSIS NO.: 200100211937  
Stimulation of dendritic cells via CD40 enhances immune responses to  
Mycobacterium tuberculosis infection.  
AUTHOR: Demangel Caroline; Palendira Umaimainthan; Feng Carl G; Heath  
Andrew W; Bean Andrew G D; Britton Warwick J(a)  
AUTHOR ADDRESS: (a)Centenary Institute of Cancer Medicine and Cell Biology,  
Newtown, NSW, 2042: wbritton@medicine.usyd.edu.au\*\*Australia  
JOURNAL: Infection and Immunity 69 (4):p2456-2461 April, 2001  
MEDIUM: print  
ISSN: 0019-9567  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

2/3/3 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11317747 EMBASE No: 2001329877  
CD40 stimulation accelerates deletion of tumor-specific CD8<sup>SUP</sup>+ T cells  
in the absence of tumor-antigen **vaccination**  
Kedl R.M.; Jordan M.; Potter T.; Kappler J.; Marrack P.; Dow S.  
R.M. Kedl, 3M Pharmaceuticals, 3M Center, St. Paul, MN 55144-1000 United  
States  
AUTHOR EMAIL: rmkedl@mmm.com  
Proceedings of the National Academy of Sciences of the United States of  
America ( PROC. NATL. ACAD. SCI. U. S. A. ) (United States) 11 SEP 2001  
, 98/19 (10811-10816)  
CODEN: PNAS A ISSN: 0027-8424  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 50

2/3/4 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

07928705 EMBASE No: 1999402576

Generation of mature dendritic cells from a CD14sup + cell line (XS52) by IL-4, TNF-alpha, IL-1beta, and **agonistic** anti-**CD40** monoclonal **antibody**

Yamada N.; Katz S.I.

Dr. S.I. Katz, Dermatology Branch, National Cancer Institute, Building 10, Bethesda, MD 20892 United States

AUTHOR EMAIL: skatz@box-s.nih.gov

Journal of Immunology ( J. IMMUNOL. ) (United States) 15 NOV 1999, 163/10 (5331-5337)

CODEN: JOIMA ISSN: 0022-1767

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 33

2/3/5 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

12918630 21656620 PMID: 11797392

[Is it possible to treat diseases by manipulation of lymphocytes?]

Ogasawara K

Second Department of Pathology, Shiga University of Medical Science, School of Medicine, Ohtsu 520-2192.

Rinsho byori. The Japanese journal of clinical pathology (Japan) Dec 2001, 49 (12) p1225-32, ISSN 0047-1860 Journal Code: 2984781R

Document type: Journal Article; Review; Review, Tutorial ; English Abstract

Languages: JAPANESE

Main Citation Owner: NLM

Record type: Completed

2/3/6 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

10488448 20021827 PMID: 10553056

Generation of mature dendritic cells from a CD14+ cell line (XS52) by IL-4, TNF-alpha, IL-1 beta, and **agonistic** anti-**CD40** monoclonal

**antibody**.

Yamada N; Katz S I

Dermatology Branch, National Cancer Institute, Bethesda, MD 20892, USA.

Journal of immunology (Baltimore, Md. : 1950) (UNITED STATES) Nov 15 1999, 163 (10) p5331-7, ISSN 0022-1767 Journal Code: 2985117R

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

2/3/7 (Item 3 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

09788182 98214894 PMID: 9554275

A novel method for enhancement of T independent responses.

Dullforce P; Sutton D; Heath A W

Division of Molecular and Genetic Medicine, University of Sheffield Medical School, U.K.

Developments in biological standardization (SWITZERLAND) 1998, 92 p195-8, ISSN 0301-5149 Journal Code: 0427140

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

2/3/8 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

131270955 CA: 131(20)270955z PATENT  
Monoclonal antibodies to CD40 ligand, pharmaceutical composition  
comprising the same and hybridomas producing the same  
INVENTOR(AUTHOR): Armitage, Richard J.; Fanslow, William C.; Spriggs,  
Melanie K.  
LOCATION: USA  
ASSIGNEE: Immunex Corporation  
PATENT: United States ; US 5961974 A DATE: 19991005  
APPLICATION: US 249189 (19940524) \*US 783707 (19911025) \*US 805723  
(19911205) \*US 969703 (19921023)  
PAGES: 59 pp., Cont.-in-part of U.S. Ser. No. 969,703, abandoned.  
CODEN: USXXAM LANGUAGE: English CLASS: 424154100; C07K-016/28A;  
A61K-039/395B; C12N-005/12B

2/3/9 (Item 2 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2002 American Chemical Society. All rts. reserv.

131270947 CA: 131(20)270947y PATENT  
Recombinant soluble CD40 ligand polypeptide and pharmaceutical  
composition containing the same  
INVENTOR(AUTHOR): Armitage, Richard J.; Fanslow, William C.; Spriggs,  
Melanie K.; Srinivasan, Subhashini; Gibson, Marylou G.; Morris, Arvia E.;  
McGrew, Jeffrey T.  
LOCATION: USA  
ASSIGNEE: Immunex Corporation  
PATENT: United States ; US 5962406 A DATE: 19991005  
APPLICATION: US 484624 (19950607) \*US 783707 (19911025) \*US 805723  
(19911205) \*US 969703 (19921023) \*US 249189 (19940524)  
PAGES: 64 pp., Cont.-in-part of U.S. Ser. No. 249,189. CODEN: USXXAM  
LANGUAGE: English CLASS: 514008000; A61K-038/18A; C07K-014/435B  
? s (agonist?) (10n) (antibod?) (10n) (cd40) (20n) (vivo)  
403137 AGONIST?  
1750059 ANTIBOD?  
16031 CD40  
1022468 VIVO  
S3 22 (AGONIST?) (10N) (ANTIBOD?) (10N) (CD40) (20N) (VIVO)  
? rd s3  
...completed examining records  
S4 11 RD S3 (unique items)  
? t s4/3/all

4/3/1 (Item 1 from file: 5)  
DIALOG(R) File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13680681 BIOSIS NO.: 200200309502  
CD40 stimulation leads to effective therapy of CD40- tumors through  
induction of strong systemic cytotoxic T lymphocyte immunity.  
AUTHOR: van Mierlo Geertje J D; den Boer Annemieke Th; Medema Jan Paul; van  
der Voort Ellen I H; Fransen Marieke F; Offringa Rienk; Melief Cornelis J  
M; Toes Rene E M(a)  
AUTHOR ADDRESS: (a)Department of Immunohematology and Bloodtransfusion,  
Leiden University Medical Center, 2300 RC, Leiden\*\*Netherlands E-Mail:  
R.E.M.Toes@Lumc.nl  
JOURNAL: Proceedings of the National Academy of Sciences of the United  
States of America 99 (8):p5561-5566 April 16, 2002  
MEDIUM: print

ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

4/3/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

13267172 BIOSIS NO.: 200100474321  
CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination.  
AUTHOR: Kedl Ross M(a); Jordan Michael; Potter Terence; Kappler John; Marrack Philippa; Dow Steven  
AUTHOR ADDRESS: (a)3M Center, 3M Pharmaceuticals, Building 270-2S-06, St. Paul, MN, 55144-1000: rmkedl@mmm.com\*\*USA  
JOURNAL: Proceedings of the National Academy of Sciences of the United States of America 98 (19):p10811-10816 September 11, 2001  
MEDIUM: print  
ISSN: 0027-8424  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

4/3/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12623767 BIOSIS NO.: 200000377269  
Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli.  
AUTHOR: Schuurhuis Danita H; Laban Sandra; Toes Rene E M; Ricciardi-Castagnoli Paola; Kleijmeer Monique J; van der Voort Ellen I H; Rea Delphine; Offringa Rienk; Geuze Hans J; Melief Cornelis J M; Ossendorp Ferry(a)  
AUTHOR ADDRESS: (a)Dept. of Immunohematology and Blood Transfusion, Leiden University Medical Center, Albinusdreef 2, Leiden\*\*Netherlands  
JOURNAL: Journal of Experimental Medicine 192 (1):p145-150 July 3, 2000  
MEDIUM: print  
ISSN: 0022-1007  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

4/3/4 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12604864 BIOSIS NO.: 200000358366  
**Agonistic** properties and in **vivo** antitumor activity of the anti-**CD40** antibody SGN-14.  
AUTHOR: Francisco Joseph A; Donaldson Karen L; Chace Dana; Siegall Clay B; Wahl Alan F(a)  
AUTHOR ADDRESS: (a)Department of Biochemistry, Seattle Genetics, Inc., 22215 26th Avenue SE, Bothell, WA, 98021\*\*USA  
JOURNAL: Cancer Research 60 (12):p3225-3231 June 15, 2000  
MEDIUM: print  
ISSN: 0008-5472



DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

4/3/5 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12571721 BIOSIS NO.: 200000325223  
CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes.  
AUTHOR: Moodycliffe Angus M; Shreedhar Vijay; Ullrich Stephen E; Walterscheid Jeffrey; Bucana Corazon; Kripke Margaret L; Flores-Romo Leopoldo(a)  
AUTHOR ADDRESS: (a)Inq.: Ms. Sue Adams, Dept. of Immunology-178, M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, 77030\*\*USA  
JOURNAL: Journal of Experimental Medicine 191 (11):p2011-2020 June 5, 2000  
MEDIUM: print  
ISSN: 0022-1007  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

4/3/6 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2002 BIOSIS. All rts. reserv.

12187499 BIOSIS NO.: 199900482348  
CD40-CD40 ligand interactions augment survival of normal mice, but not CD40 ligand knockout mice, challenged orally with Salmonella dublin.  
AUTHOR: Marriott Ian; Thomas Elaine K; Bost Kenneth L(a)  
AUTHOR ADDRESS: (a)Department of Biology, University of North Carolina at Charlotte, 9201 University City Blvd., Charlotte, NC, 28223\*\*USA  
JOURNAL: Infection and Immunity 67 (10):p5253-5257 Oct., 1999  
ISSN: 0019-9567  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English

4/3/7 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11317747 EMBASE No: 2001329877  
CD40 stimulation accelerates deletion of tumor-specific CD8SUP+ T cells in the absence of tumor-antigen vaccination  
Kedl R.M.; Jordan M.; Potter T.; Kappler J.; Marrack P.; Dow S.  
R.M. Kedl, 3M Pharmaceuticals, 3M Center, St. Paul, MN 55144-1000 United States  
AUTHOR EMAIL: rmkedl@mmm.com  
Proceedings of the National Academy of Sciences of the United States of America ( PROC. NATL. ACAD. SCI. U. S. A. ) (United States) 11 SEP 2001 , 98/19 (10811-10816)  
CODEN: PNASA ISSN: 0027-8424  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 50

4/3/8 (Item 2 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

11117336 EMBASE No: 2001140203  
Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation  
Hixon J.A.; Blazar B.R.; Anver M.R.; Wiltout R.H.; Murphy W.F.  
W.J. Murphy, SAIC-Frederick, NCI-FCRDC, Bldg. 567, Frederick, MD 21702  
United States  
AUTHOR EMAIL: murphyw@mail.ncifcrf.gov  
Biology of Blood and Marrow Transplantation (BIOL. BLOOD MARROW TRANSPLANT. ) (United States) 2001, 7/3 (136-143)  
CODEN: BBMTF ISSN: 1083-8791  
DOCUMENT TYPE: Journal ; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 20

4/3/9 (Item 3 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

10779484 EMBASE No: 2000259569  
Immature dendritic cells acquire cd8sup + cytotoxic t lymphocyte priming capacity upon activation by t helper cell-independent or-dependent stimuli  
Schuurhuis D.H.; Laban S.; Toes R.E.M.; Ricciardi-Castagnoli P.; Kleijmeer M.J.; van der Voort E.I.H.; Rea D.; Offringa R.; Geuze H.J.; Melief C.J.M.; Ossendorp F.  
F. Ossendorp, Immunohematol./Blood Transfus. Dept., Leiden University Medical Center, Albinusdreef 2, RC Leiden Netherlands  
AUTHOR EMAIL: f.a.ossendorp@LUMC.nl  
Journal of Experimental Medicine ( J. EXP. MED. ) (United States) 03 JUL 2000, 192/1 (145-150)  
CODEN: JEMEA ISSN: 0022-1007  
DOCUMENT TYPE: Journal; Article  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 27

4/3/10 (Item 4 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2002 Elsevier Science B.V. All rts. reserv.

10736643 EMBASE No: 2000216663  
A dual function for CD40 agonists  
Zanelli E.; Toes R.E.M.  
E. Zanelli, Dept. of Immuno./Blood tranfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden Netherlands  
AUTHOR EMAIL: r.e.m.toes@lumc.nl  
Nature Medicine ( NAT. MED. ) (United States) 2000, 6/6 (629-630)  
CODEN: NAMEF ISSN: 1078-8956  
DOCUMENT TYPE: Journal; Short Survey  
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH  
NUMBER OF REFERENCES: 9

4/3/11 (Item 1 from file: 155)  
DIALOG(R)File 155:MEDLINE(R)

09418246 97321353 PMID: 9178074  
The importance of efficacy and partial agonism in evaluating models of B lymphocyte activation.

Hodgkin P D; Chin S H; Bartell G; Mamchak A; Doherty K; Lyons A B;  
Hasbold J  
Medical Foundation of the University of Sydney, Centenary Institute for  
Cancer Medicine and Cell Biology, Newtown, Australia.  
p.hodgkin@centenary.usyd.edu.au  
International reviews of immunology (SWITZERLAND) 1997, 15 (1-2)  
p101-27, ISSN 0883-0185 Journal Code: 8712260  
Document type: Journal Article; Review; Review, Tutorial  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed  
? t s4/7/11

4/7/11 (Item 1 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)

09418246 97321353 PMID: 9178074

The importance of efficacy and partial agonism in evaluating models of B  
lymphocyte activation.

Hodgkin P D; Chin S H; Bartell G; Mamchak A; Doherty K; Lyons A B;  
Hasbold J

Medical Foundation of the University of Sydney, Centenary Institute for  
Cancer Medicine and Cell Biology, Newtown, Australia.  
p.hodgkin@centenary.usyd.edu.au

International reviews of immunology (SWITZERLAND) 1997, 15 (1-2)  
p101-27, ISSN 0883-0185 Journal Code: 8712260  
Document type: Journal Article; Review; Review, Tutorial  
Languages: ENGLISH  
Main Citation Owner: NLM  
Record type: Completed

Immunologists have developed a range of in vitro techniques for probing  
the receptor mediated response of cells comprising the immune system. An  
important and ubiquitous method is the use of **antibodies** in either  
soluble or aggregated form to engage cell surface receptors and transmit a  
signal. Models of cell and molecular interactions, derived from the use of  
these **antibodies**, form the basis of our efforts to understand and  
explain the corresponding in **vivo** systems. However, interpreting in  
vitro experiments and distinguishing between alternative models is  
difficult. This complexity is illustrated here using B cell stimulation by  
surface immunoglobulin and **CD40**. The fluorescent cell labelling dye  
carboxyfluorescein, diacetate, succinimidyl ester (CFSE) is used to show  
that many anti-Ig and **CD40** stimulatory agents, used to assess the  
role of B cells and lymphokines, are partial **agonists**. By modelling  
each step in B cell signalling, activation and division it is possible to  
show that small changes in signal contributed by a second receptor can  
generate numerous distinct dose response curves that are highly dependent  
on the "efficacy" of signal transmission by the primary ligand and the  
number of cell divisions taken in culture. Differences in dose response  
curves become particularly striking if the primary activating stimulus is a  
partial agonist. Although exemplified here with B cell stimulation the  
conclusions are applicable to other in vitro activation systems and suggest  
ways to improve both the design and interpretation of in vitro experiments.  
(26 Refs.)

Record Date Created: 19970717  
?